© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Novavax, Inc. (NVAX) stock surged +4.83%, trading at $8.25 on NASDAQ, up from the previous close of $7.87. The stock opened at $8.01, fluctuating between $7.85 and $8.30 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 06, 2026 | 8.01 | 8.31 | 7.85 | 8.25 | 3.25M |
| Feb 05, 2026 | 8.17 | 8.32 | 7.84 | 7.87 | 4.13M |
| Feb 04, 2026 | 8.42 | 8.62 | 8.16 | 8.27 | 3.5M |
| Feb 03, 2026 | 8.64 | 8.85 | 8.09 | 8.37 | 3.76M |
| Feb 02, 2026 | 8.67 | 8.87 | 8.44 | 8.69 | 3.32M |
| Jan 30, 2026 | 9.22 | 9.29 | 8.65 | 8.85 | 5M |
| Jan 29, 2026 | 9.25 | 9.60 | 9.23 | 9.44 | 4.48M |
| Jan 28, 2026 | 9.74 | 9.94 | 9.16 | 9.23 | 5.28M |
| Jan 27, 2026 | 9.75 | 10.20 | 9.62 | 9.82 | 6.78M |
| Jan 26, 2026 | 9.32 | 10.02 | 9.25 | 9.63 | 6.83M |
| Jan 23, 2026 | 9.70 | 9.70 | 9.15 | 9.17 | 7.57M |
| Jan 22, 2026 | 9.86 | 10.13 | 9.49 | 9.75 | 9.34M |
| Jan 21, 2026 | 8.28 | 9.98 | 8.20 | 9.90 | 16.36M |
| Jan 20, 2026 | 8.22 | 8.75 | 7.98 | 8.20 | 11.82M |
| Jan 16, 2026 | 7.77 | 8.33 | 7.73 | 8.01 | 5.44M |
| Jan 15, 2026 | 8.04 | 8.15 | 7.76 | 7.78 | 5.84M |
| Jan 14, 2026 | 8.47 | 8.53 | 7.89 | 8.19 | 7.49M |
| Jan 13, 2026 | 7.85 | 8.81 | 7.84 | 8.67 | 11.06M |
| Jan 12, 2026 | 7.30 | 7.79 | 7.15 | 7.75 | 3.69M |
| Jan 09, 2026 | 7.38 | 7.55 | 7.26 | 7.27 | 2.77M |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Employees | 952 |
| Beta | 2.37 |
| Sales or Revenue | $983.71M |
| 5Y Sales Change% | 1.977% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |